Skip to content

Recursion Pharmaceuticals, Inc. RXRX Balance Sheet Statement

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
$665.18M-11.8%$753.92M+13.0%$667.15M+25.0%$533.85M+4.8%$509.16M-15.6%
$709.56M-12.7%$812.85M+13.8%$714.11M+21.6%$587.16M+0.5%$584.15M-18.2%
$95.81M-7.8%$103.93M-7.0%$111.71M-6.9%$120.04M-5.4%$126.83M-10.1%
$160.17M-1.2%$162.16M+0.1%$162.04M-1.4%$164.27M+3.9%$158.11M+6.2%
$294.07M-5.1%$309.9M-3.9%$322.34M-5.6%$341.32M+1.6%$335.79M0.0%
$1.34B-9.1%$1.47B+5.3%$1.4B+7.5%$1.3B-0.2%$1.31B-9.9%
$71.72M-6.2%$76.45M-4.4%$79.95M+17.1%$68.27M+29.5%$52.72M+61.0%
$32.79M-12.8%$37.61M-20.6%$47.36M+19.3%$39.69M+0.1%$39.65M-35.8%
$9.27M+1.9%$9.09M+1.9%$8.92M+1.9%$8.75M+1.9%$8.59M
$129.7M-12.2%$147.71M-4.8%$155.1M-5.4%$164.03M+15.5%$141.98M-24.3%
$7.18M-24.9%$9.56M-19.6%$11.9M-16.2%$14.2M-13.7%$16.45M-13.5%
$314.75M-8.3%$343.27M-2.6%$352.58M-8.0%$383.21M+3.2%$371.29M-10.3%
2B0.0%2B0.0%2B0.0%2B0.0%2B+49,999,900%
-$2.19B-5.7%-$2.08B-5.5%-$1.97B-9.0%-$1.81B-10.5%-$1.63B-14.1%
$1.02B-9.4%$1.13B+8.0%$1.05B+13.9%$919.15M-1.6%$933.95M-9.7%
$1.34B-9.1%$1.47B+5.3%$1.4B+7.5%$1.3B-0.2%$1.31B-9.9%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Recursion Pharmaceuticals, Inc.'s total assets?
Recursion Pharmaceuticals, Inc. (RXRX) holds $1.3B in total assets, up 2.6% year over year.
How much debt does Recursion Pharmaceuticals, Inc. have?
Recursion Pharmaceuticals, Inc. carries $88.6M in total debt against $1.0B of shareholders' equity, a debt-to-equity ratio of 0.09.
How much cash does Recursion Pharmaceuticals, Inc. have?
Recursion Pharmaceuticals, Inc. holds $665.2M in cash and equivalents.
Can Recursion Pharmaceuticals, Inc. cover its short-term obligations?
Its current ratio is 5.47 — current assets exceed current liabilities.
Where does Recursion Pharmaceuticals, Inc.'s balance sheet data come from?
Every line is extracted from Recursion Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.